Skip to main content
. Author manuscript; available in PMC: 2024 May 25.
Published in final edited form as: J Autoimmun. 2023 Sep 22;140:103112. doi: 10.1016/j.jaut.2023.103112

Figure 5. Rapamycin restrains autophagy and oxidative stress and reduces aPL production and Ito cell expansion in TALKO mice.

Figure 5.

WT and TALKO mice were with rapamycin (3 mg/kg sc 3 times weekly) from 35 weeks of age for 10 weeks. A, Western blot analysis of LC3, p62 and NDUFS3 expression, and mTORC1 pathway activation in livers of WT, TALKO, ARKO and DKO mice. Representative western blots (left panels) and cumulative analysis of LC3-I, p62, NDUFS3, phosphorylated (p-mTOR) and total mTOR, and p4E-BP1 protein levels were been determined relative to β-actin loading controls (right panels) in age-matched WT, TALKO, ARKO, and DKO mice and compared to WT and TALKO mice treated with rapamycin. *, p < 0.05 relative to WT based on two-tailed t-test. B, Effect of in vivo rapamycin treatment on PON1 protein levels in the liver. C, Effect of in vivo rapamycin treatment on PON1 protein levels in the serum. D, Effect of in vivo rapamycin treatment on serum aPL, ACLA and anti-Apo-H, antibody levels and Ito cell counts in the liver. Analyses were performed in age-matched untreated control WT, TALKO, ARKO and DKO female mice and rapamycin-treated WT and TALKO female mice. *, p < 0.05 relative to WT based on two-tailed t-test.